Europe’s leading exchange for life sciences companies
Swiss financial institutions manage more than one-quarter of the world’s offshore assets and represent the backbone of Switzerland’s strong financial marketplace. As a result, companies listed on SIX Swiss Exchange achieve a high level of visibility within this financially potent investor community.
In Switzerland, the life sciences industry in particular has developed over the past years into an internationally recognised and strongly emphasized sectoral focal point:

1. In Europe, SIX Swiss Exchange has grown to become the most important securities exchange in terms of the total market capitalisation of listed life sciences companies: 42% of Europe’s life sciences market capitalisation is attributable to the SIX Swiss Exchange.
2. Collectively, these representatives of the industry account for roughly one-third of the overall market capitalisation of the Swiss equity market.
3. Listed companies in the life sciences field such as Novartis, Roche and Actelion engender an environment that exudes global charisma.
4. Differentiated sector-specific indicators such as the SXI LIFE SCIENCES® and SXI Bio+Medtech® indices, as well as the unusually broad analyst coverage of this particular sector, ensure transparency and outstanding visibility.
5. The SIX Swiss Exchange has seen the largest biotech IPOs in Europe in terms of money raised on the day of the IPO every year since 2004 and was the only regulated exchange who recently attracted European biotech crossborder-IPOs.

With a public offering of securities in Switzerland, and thanks to the tremendous placing power afforded by the Swiss-based investment banks, life science companies gain access to a sectorally experienced, highly competent and broadly international circle of investors.
Moreover, the location-specific advantages of Switzerland and favourable general conditions contribute to the attractiveness of an initial public offering on the SIX Swiss Exchange:

1. The Continental European marketplace with the most pronounced international orientation
2. A leading financial centre for equity-focused institutional investors
3. A strong private banking industry with a broad investor base
4. Multilingual and multicultural investors
5. Focus on life sciences and small- and mid-caps
6. Numerous banks with established in-house research departments
7. Active bond and derivatives markets
8. An attractive, market-oriented regulatory environment thanks to self-regulation
9. Acceptance of various accounting standards (US-GAAP, IFRS, Swiss GAAP ARR and additional internationally recognised standards)
10. Low foreign exchange risk (listing in various currencies is possible)

Further information on the topic of IPOs on the SIX Swiss Exchange can be accessed at: www.six-swiss-exchange.com/download/about/div_pub/swx_ipoguide_en.pdf

Should you have further questions with regard to a public offering of securities, the various stock market segments or any other exchange-related topic, please feel free to contact our Issuer & Investor Relations team.

SIX Swiss Exchange
Issuer & Investor Relations
Selnaustrasse 30, Postfach, CH-8021 Zürich
T +41(0)58 854 22 45   F +41(0)58 854 22 40
E-mail: ipo@six-swiss-exchange.com

www.six-swiss-exchange.com

back to top

DyoDelta Biosciences Ltd., is a London based company specialising in providing Business Development and Due Diligence support to companies and investors in the Pharma / Biotech sector.

DyoDelta Biosciences' team averages more than 20 years experience per person and more than 150 years of cumulative experience.  DyoDelta Biosciences has thousands of contacts at the senior corporate level worldwide and across the life sciences industry.  The team's executives have put together multiple types of deals, including R&D collaborations, strategic alliances, product licensing, acquisitions, disposals, financings and local geography partnering, with NPVs adding to billions of dollars.

DyoDelta Biosciences covers Europe, the US and Japan, in guiding and supporting pharma and biotech companies, investors, institutions and organisations in corporate transactions, evaluation and due diligence.

Corporate deals with pharma companies are key to progressing development, providing funding, validation and also the trigger to investors for either an IPO or further funding. 
DyoDelta Biosciences provides support to professional investors (funds) in the pharma and biotech sector the following areas:

• Market Research and Analysis
• Identification of suitable opportunities
• Deal Sourcing
• Industry Contacts
• Commercial & Technical Evaluation
• Due Diligence

For more information, please contact:
Dimitri F. Dimitriou, M.Sc.
Chief Executive Officer
DyoDelta Biosciences Ltd
Berkeley Square House
Berkeley Square
London W1J 6BD
UK

Tel:  +44 20 7396 5572
Fax:  +44 20 7396 5599

http://www.dyodelta.com/Investor_Support.html

back to top

Global Life Science Ventures (GLSV) is a leading, independent venture capital fund focusing exclusively on the life sciences. GLSV is dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund may also invest in selected later stage companies, including buy-outs. For this purpose, GLSV provides finance, advice and access to expertise and networks. The group currently advises and manages funds totalling more than € 200 million. With offices in Germany and Switzerland, GLSV acts as one team with a global perspective.

For more information, please see our website: www.glsv-vc.com

back to top

Our active ingredient is Innovation

At Merck Serono, we are actively committed to bringing therapeutic innovations to patients. We specialize in the treatment of cancer, neurodegenerative diseases, infertility, endocrine and metabolic disorders, cardiovascular diseases and other conditions with unmet medical needs.

Around the world, over 17,000 employees work to discover, develop, manufacture and commercialize Merck Serono’s prescription therapies, available in over 150 countries.
We are internationally recognized as a biotechnology leader, with innovative and successful products along with a well-stocked and promising development pipeline. Specialized know-how in research and production means that we are able to ensure absolutely high-quality manufacturing, a key success factor especially in the biopharmaceutical industry.

In 2007, sales of Merck Serono products generated total revenues of €4.5 billion. We devote 20% of these earnings to the pursuit of innovative new therapies through our own research and development, strategic alliances and agreement.

http://www.serono.com

back to top